Chronic Obstructive Pulmonary Disease- Pipeline Analysis 2018
There are total 141 molecules in pipeline (Company Molecules 90, University & Institute Molecules 51) in different phases of development. There are total 141 m...
Executive Abstract
There are total 141 molecules in pipeline (Company Molecules 90, University & Institute Molecules 51) in different phases of development. As per GervanoRA Pipeline Analysis, One molecule is expected to get regulatory approval in 2018; three molecules are expected get regulatory approvals in 2019 and nine molecules in 2020. Report provides comprehensive information on the therapeutics under development for COPD with analysis by stage of development, drug class, mechanism of action (MoA), route of administration (RoA), geography and developers (Companies, Universities and Institutes).
Unlock Report Access
Complete this brief form for instant PDF access.
Related Executive Research
White Paper
How To Choose An Immunoassay Platform For Cell & Gene Therapy Bioanalysis
The key factors to automating assay development to get results quicker Given the recent approval of an adeno-associated viral (AAV) vector gene therapy for spi...
White Paper
Increasing Patient Engagement and Helping Clinical Trials Reach Full Potential with the Clinical Research as a Care Option Model
Only 3% of people with cancer participate in clinical trials. CRAACO seamlessly integrates clinical research with medical care, so more patients and physicians...
White Paper
How to Use Risk-Based Monitoring and Clinical CAPA to Ensure Compliance
If your company is a sponsor or a CRO that conducts clinical research for a sponsor, how effective are your risk management and clinical CAPA processes? Are you...